Log in to search using one of your social media accounts:

 

A Patient's Journey: Taming the Glucose Monster
(MedPage Today) -- Dramatic success with metformin, diet, and microbiome tweaks (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 12, 2018 Category: Endocrinology Source Type: news

TOO TOXIC to swallow: Up to a third of diabetics don't take their pills because of the debilitating side effects
(Natural News) According to a group of researchers, at least a third of diabetics do not take their medication due to fear of possible side effects. Diabetics in the U.K. are often prescribed metformin, the most commonly prescribed drug for type 2 diabetes. While there is no definite data on how many of the 3.4 million... (Source: NaturalNews.com)
Source: NaturalNews.com - January 5, 2018 Category: Consumer Health News Source Type: news

Metformin vs. Glucovance
Title: Metformin vs. GlucovanceCategory: MedicationsCreated: 1/5/2018 12:00:00 AMLast Editorial Review: 1/5/2018 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - January 5, 2018 Category: Endocrinology Source Type: news

Metformin Tied to Worse Pregnancy Outcomes, Diabetes Likely Culprit Metformin Tied to Worse Pregnancy Outcomes, Diabetes Likely Culprit
Women with pregestational diabetes who are taking metformin are at increased risk for poor pregnancy outcomes, new findings show.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Segluromet (Ertugliflozin and Metformin Hydrochloride Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 28, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Segluromet (ertugliflozin and metformin hydrochloride) for Type 2 Diabetes
KENILWORTH, N.J.& NEW YORK--(BUSINESS WIRE) December 22, 2017 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 22, 2017 Category: Drugs & Pharmacology Source Type: news

Three in 10 Doses of Metformin Not Taken by Patients With T2D Three in 10 Doses of Metformin Not Taken by Patients With T2D
Patients with type 2 diabetes (T2D) are less likely to take the most commonly prescribed diabetes drug, metformin, than other, newer medications, say UK researchers, who suggest adverse events may be to blame.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 22, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Metformin use found safe during pregnancy
Pregnant women taking metformin to treat conditions such as PCOS do not show an increase in adverse pregnancy outcomes, according to research in the BritishJournal of Clinical Pharmacology.Medpage Today (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 22, 2017 Category: Endocrinology Source Type: news

Metformin Found Safe in Pregnant Women With Diabetes (CME/CE)
(MedPage Today) -- Adverse outcomes tied to diabetes, not the drug (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 21, 2017 Category: Cardiology Source Type: news

Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
(Wiley) New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2017 Category: International Medicine & Public Health Source Type: news

Study: Most commonly-prescribed diabetes drug linked to lowest rate of compliance
Patients who take the most-commonly prescribed diabetes medication, metformin, are the least likely to adhere to a prescribed regimen, according to a study published in the journal Diabetes, Obesity and Metabolism. Researchers from the University of Surrey looked at data from 1.6 million people with Type II diabetes across 48 trials and found that 30% of metformin doses prescribed to patients are not taken, compared to 23% for sulfonylureas and 20% for pioglitazone. Get the full story at our sister site, Drug Delivery Business News. The post Study: Most commonly-prescribed diabetes drug linked to lowest rate of compli...
Source: Mass Device - December 18, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Pharmaceuticals Research & Development Eli Lilly & Co. Novo Nordisk Sanofi-Aventis Source Type: news

One in three diabetic patients not taking drugs for fear of side effects
A study inDiabetes, Obesity and Metabolism reports that a third of diabetic patients are not taking metformin, and researchers hypothesise it may be due to the side effects of the drug.Daily Mail (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 18, 2017 Category: Endocrinology Source Type: news

Up to a third of diabetics won't take their pills
For many people, taking the Metformin pill is an essential - yet University of Surrey researchers found 30 per cent of prescribed doses are never taken. (Source: the Mail online | Health)
Source: the Mail online | Health - December 18, 2017 Category: Consumer Health News Source Type: news

Third of people not taking their prescribed diabetes medication due to side effects
(University of Surrey) Diabetes patients who take the most commonly prescribed diabetes drug, metformin, are the least likely to follow medical advice regarding their medication due its side effects, a new article in the journal Diabetes, Obesity and Metabolism reports. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2017 Category: International Medicine & Public Health Source Type: news

Mother ’ s Weight May Affect Metformin's Influence on Fetal Growth Mother ’ s Weight May Affect Metformin's Influence on Fetal Growth
Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 12, 2017 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Metformin May Up Survival in Older Men With Moderate CKD Metformin May Up Survival in Older Men With Moderate CKD
Veterans with type 2 diabetes and moderate chronic kidney disease fared well on metformin in an observational study; more research is needed to see whether this is also the case in other patient populations.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 11, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Medical News Today: Metformin may prevent multidrug-resistant breast cancer
Type 2 diabetes drug metformin has been found to inhibit and reverse the development of multidrug resistance in vitro in breast cancer cells. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 7, 2017 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Diabetes drug and aspirin boosts cancer drug effectiveness
Metformin may slow breast cancer growth, a study by the University of Saskatchewan in Canada found. Adding aspirin to a cancer drug could help combat pancreatic, lung and colorectal cancers. (Source: the Mail online | Health)
Source: the Mail online | Health - December 6, 2017 Category: Consumer Health News Source Type: news

Diabetes drug metformin 'may help reverse breast cancer drug resistance'
A WIDELY-used diabetes drug may have the ability to reverse breast cancer drug resistance, research suggests. (Source: Daily Express - Health)
Source: Daily Express - Health - December 6, 2017 Category: Consumer Health News Source Type: news

Diabetes drug metformin inhibits multidrug-resistant breast cancer
(PLOS) The drug metformin, typically prescribed to treat type 2 diabetes, keeps breast cancer cells from developing multiple drug resistance (MDR) and can reverse MDR after it ¹ s appeared, according to a study published Dec. 6, 2017 in the open-access journal PLOS ONE by Terra Arnason from the University of Saskatchewan, Canada, and colleagues. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2017 Category: Cancer & Oncology Source Type: news

Scientists find natural mimetics of anti-cancer & anti-aging drugs metformin and rapamycin
Researchers from the Biogerontology Research Foundation, Insilico Medicine, Life Extension and other institutions announce the publication of a landmark study in the journal Aging on the identification of natural mimetics of metformin and rapamycin. Metformin, a common type 2 diabetes drug, and rapamycin, a common anti-rejection drug, have both been shown to have substantial anti-aging and anti-cancer effects in a variety of model organisms. (Source: World Pharma News)
Source: World Pharma News - November 29, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Scientists find natural mimetics of anti-cancer & anti-aging drugs metformin and rapamycin
(Biogerontology Research Foundation) Researchers from the Biogerontology Research Foundation, Insilico Medicine , Life Extension and other institutions announce the publication of a landmark study in the journal Aging on the identification of natural mimetics of metformin and rapamycin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 29, 2017 Category: International Medicine & Public Health Source Type: news

Cardiovascular Effects of DPP-4 Inhibitors Tied to Metformin Use Cardiovascular Effects of DPP-4 Inhibitors Tied to Metformin Use
Concomitant metformin use is associated with cardiovascular outcomes of the use of dipeptidyl peptidase 4 (DPP-4) inhibitors, according to a meta-analysis of three clinical trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Jentadueto ® (linagliptin/metformin hydrochloride) tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe
Jentadueto ® (linagliptin/metformin hydrochloride) tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Type 2 diabetes: Synjardy ® (empagliflozin/metformin hydrochloride) approved in the European Union
Type 2 diabetes: Synjardy ® (empagliflozin/metformin hydrochloride) approved in the European Union (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Springer Nature continues to advance sharing
Over 3.25 million article shares in SharedIt’s first year Articles have been successfully shared by authors, subscribers and media outlets over 3.25 million times during the first year of SharedIt, Springer Nature’s free content sharing initiative. SharedIt was launched in October 2016 and covers over 2,700 journals including all the Springer Nature-owned portfolio and over 1,000 co-owned and partner-owned journals. This industry-leading initiative enables authors and subscribers to post links to free-to-read versions of research articles anywhere, including social media platforms, repositories, websites, schol...
Source: News from STM - November 27, 2017 Category: Databases & Libraries Authors: STM Publishing News Tags: Editorial Featured Source Type: news

Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet ® (Metformin Hydrochloride Oral Solution) Manufactured by a Contract Manufacturer due to Microbial Contamination
Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” including its subsidiaries and/or associate companies) is voluntarily recalling two lots of Riomet® (Metformin Hydrochloride Oral Solution), 500 mg/5mL, to the retail level (Class II Recall). This product is manufactured for SPII by a contract manufacturer. The Riomet® (Metformin Hydrochloride Oral Solution) has been found to be contaminated (Scopulariopsis brevicaulis). The contamination was discovered during sample p...
Source: Food and Drug Administration - November 24, 2017 Category: Food Science Source Type: news

Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet ® (Metformin Hydrochloride Oral Solution) Manufactured by a Contract Manufacturer due to Microbial Contamination
Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “ Sun Pharma ” including its subsidiaries and/or associate companies) is voluntarily recalling two lots of Riomet ® (Metformin Hydrochloride Oral Solution), 500 mg/5mL, to the retail level (Class II Recall). This product is manufactured for SPII by a contract manufacturer. The Riomet ® (Metformin Hydrochloride Oral Solution) has been found to be contaminated (Scopulariopsis brevicaulis). The contamination was discovered during samp...
Source: Food and Drug Administration - November 24, 2017 Category: Food Science Source Type: news

Metformin and Growth Rate of Abdominal Aortic Aneurysms Metformin and Growth Rate of Abdominal Aortic Aneurysms
Dr Lowenfels comments on a study that investigated whether metformin could significantly slow the growth rate of this very common disease.Medscape General Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 16, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery Viewpoint Source Type: news

The Role of Metformin in PCOS-Related Infertility The Role of Metformin in PCOS-Related Infertility
Peter Kovacs comments on a new guideline from the American Society for Reproductive Medicine on the use of metformin for ovulation induction in women with polycystic ovary syndrome.Medscape Ob/Gyn (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2017 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Viewpoint Source Type: news

Synjardy XR Extended-release Tablets (Empagliflozin and Metformin Hydrochloride Extended-release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 30, 2017 Category: Drugs & Pharmacology Source Type: news

Diabetes Medications Have Different Effects on the Liver Diabetes Medications Have Different Effects on the Liver
For people with advanced liver fibrosis and type 2 diabetes, metformin is better than sulfonylureas, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Obesity, Type 2 Diabetes and Metformin Obesity, Type 2 Diabetes and Metformin
Metformin is commonly used in the management of type 2 diabetes, but could it also provide benefit in the treatment of obesity in children?Archives of Disease in Childhood (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2017 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news

Statin use link to heightened type 2 diabetes risk in some people
30% higher risk of diabetes in susceptible individuals Related items fromOnMedica Statins' side effects have been overstated, study suggests Starting statins not beneficial in many older adults Taking statins linked to improved heart structure and function Almost 12 million more people should be on statins Metformin doesn ’t help HbA1c in teens with type 1 diabetes (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 24, 2017 Category: UK Health Source Type: news

Insulin pumps linked to fewer diabetes complications
Pumps also associated with better glycaemic control and lower insulin dosage than injections Related items fromOnMedica Glycosylated haemoglobin (HbA1c) and screening for diabetes Metformin doesn ’t help HbA1c in teens with type 1 diabetes Glucose self-monitoring may not improve control in non-insulin-treated type 2 diabetes Bionic pancreas outperforms insulin pump (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 12, 2017 Category: UK Health Source Type: news

Prediabetes drug increases risk of diabetes!
Raise your hand if your doctor has ordered a blood test to check your glucose. Most do, whether or not you have symptoms of diabetes. If your fasting blood sugar is 125 mgm/dL or above you are considered a diabetic. But if your number comes in between 108 and 125 they’ll say you have “prediabetes.”  That’s a condition where your cells have a resistance to the hormone insulin. Your body uses insulin to put glucose into your cells where it can provide energy. But with insulin resistance, your cells are slow to take up glucose. It builds up in your blood.  Over a lifetime, 70-75% of people ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Randall Hall Tags: Health Men's Health Women's Health Source Type: news

Melior begins dosing MLR-1023 in Phase IIb trial to treat type 2 diabetes
US-based Melior Pharmaceuticals I has begun dosing in a Phase IIb trial aimed at evaluating the efficacy of MLR-1023, an oral insulin sensitizer, in adult patients with uncontrolled type 2 diabetes on metformin therapy. (Source: Drug Development Technology)
Source: Drug Development Technology - October 4, 2017 Category: Pharmaceuticals Source Type: news

Comparison of Myo-Inositol and Metformin in PCOS Comparison of Myo-Inositol and Metformin in PCOS
A new study compares the effects of treatment with myo-inositol or metformin among women with PCOS.Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 3, 2017 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

Diabetes drug cuts Parkinson's risk by 28%
Researchers from the University of Bergen in Norway found glitazones (GTZs) have a protective effect. The figure is in comparison with users of metformin, the most common type 2 drug. (Source: the Mail online | Health)
Source: the Mail online | Health - October 2, 2017 Category: Consumer Health News Source Type: news

Pioglitazone, Sulfonylureas Safe and Effective in Type 2 Diabetes Pioglitazone, Sulfonylureas Safe and Effective in Type 2 Diabetes
They may not boast a cardiovascular benefit like other newer drugs, but these drugs can safely be added to metformin to manage type 2 diabetes.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 29, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Ertugliflozin: Promise From Yet Another SGLT-2 Inhibitor (CME/CE)
(MedPage Today) -- Assessed as triple agent therapy when added to metformin, sitagliptin (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 25, 2017 Category: Cardiology Source Type: news

Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials
In two phase 3 trials, the SGLT2 inhibitor ertugliflozin for the treatment of type 2 diabetes that is uncontrolled with metformin alone or with sitagliptin demonstrated safety and efficacy at 52 weeks.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

REMOVAL Update: More Benefits of Metformin in T1D REMOVAL Update: More Benefits of Metformin in T1D
New REMOVAL data presented at EASD 2017 reveal effects of metformin on renal function, biomarkers, and more in patients with type 1 diabetes.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 22, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Sulfonylureas, Pioglitazone Similarly Safe for Add-On Therapy in Type 2 Diabetes (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD For patients with type 2 diabetes inadequately controlled with metformin, add-on treatment with either a sulfonylurea or pioglitazone seems similarly safe over the long-term, according to an open-label, multicenter study in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 14, 2017 Category: Primary Care Source Type: news

For Metformin Add-On, No Winner in Head-to-Head CVD Trial (CME/CE)
(MedPage Today) -- Pioglitazone largely similar to sulfonylurea in pragmatic TOSCA.IT trial (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 13, 2017 Category: Urology & Nephrology Source Type: news

Deals this week: Mundipharma Medical Company, Cooper Pharmal Sarl, Merck
Mundipharma Medical Company will exclusively distribute INVOKANA (canagliflozin) and VOKANAMET (canagliflozin and metformin) in the European Economic Area (EEA) and Switzerland, under an agreement signed with drug developer and manufacturer Janssen P … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Janssen and Mundipharma sign distribution deal for type 2 diabetes treatments
Janssen Pharmaceutica has entered an exclusive distribution agreement with Mundipharma Medical Company for Invokana (canagliflozin) and Vokanamet (a fixed-dose combination therapy of canagliflozin and metformin) to treat patients with type 2 diabetes … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 4, 2017 Category: Pharmaceuticals Source Type: news

Janumet (Sitagliptin Metformin HCL) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 28, 2017 Category: Drugs & Pharmacology Source Type: news

Metformin Still Cost-effective for Diabetes Prevention Metformin Still Cost-effective for Diabetes Prevention
Metformin plus vitamin B12 supplementation remains cost-effective for preventing progression to diabetes compared with placebo and lifestyle changes, researchers report.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 26, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

$820 million wasted in failing to attempt Type 2 diabetes prevention efforts
(University of South Florida (USF Health)) Lifestyle intervention is the best approach in preventing Type 2 diabetes. However, most patients don't follow through in having a balanced diet and exercise. Prescribing metformin can save $820 million annually in healthcare costs and reduce the number of Type 2 diabetes patients by 20%. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 4, 2017 Category: International Medicine & Public Health Source Type: news